

ASA: botox injections beneficial for migraine in children

October 24 2017



(HealthDay)—OnabotulinumtoxinA (Botox) injections are beneficial for

pediatric patients with chronic migraine, according to a study presented at the annual meeting of the American Society of Anesthesiologists, being held Oct. 21 to 25 in Boston.

Michael-David Calderon, from UC Irvine Health in Orange, California, and colleagues performed a retrospective chart review for [pediatric patients](#) aged 8 to 17 years who received onabotulinumtoxinA for treatment of [chronic migraine](#). Data were included for 10 patients receiving Botox across 35 injections; one patient was lost to follow-up.

The researchers found that there were statistically significant changes in migraine intensity (from 6 to 4 on a linear 0-to-10 scale), frequency (from 15.5 to four per month), and duration (eight to 0.75 hours) from pre- to post-treatment. There was no statistically significant change in concomitant medications and oral morphine equivalency, although clinically relevant decreases were seen.

"Many current [migraine](#) medications have side effects including sedation, dry mouth, and confusion, which aren't well-tolerated in children and teens," one co-author said in a statement. "Our research of Botox is part of an effort to find better treatments for children and teens with migraines so they can realize their full potential."

More information: [Abstract](#)
[More Information](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: ASA: botox injections beneficial for migraine in children (2017, October 24) retrieved 27 April 2024 from <https://medicalxpress.com/news/2017-10-asa-botox-beneficial-migraine-children.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.